{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:50:59Z","timestamp":1790725859722,"version":"4.1.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Pathogenic variants in\n                      <jats:italic>LRRK2<\/jats:italic>\n                      lead to increased kinase activity, and LRRK2 kinase inhibition is being explored in clinical studies as a therapeutic approach for Parkinson\u2019s Disease (PD). LRRK2 inhibitors reduce urine levels of bis(monoacylglycerol)phosphate (BMP), a key endolysosomal lipid involved in glycosphingolipid (GSL) catabolism, in preclinical models and clinical subjects. However, how LRRK2 regulates BMP and its significance with respect to lysosomal dysfunction in PD are poorly defined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a combination of genetic and pharmacological approaches to modulate LRRK2 kinase activity, we explored the mechanisms by which LRRK2 can regulate the levels of BMP and PD-relevant GSLs across cellular models, including iPSC-derived microglia, and in tissues and biofluids from mice using mass spectrometry. The impact of LRRK2 activity on various aspects of lysosomal function, including endolysosomal GCase activity, was assessed using live-cell imaging and lysosomal immunoprecipitation. We employed imaging mass-spectrometry and FACS-based methods to specifically examine how LRRK2 modulates BMP and GSL levels across different cell types and regions of the brain. To confirm the relevance of our findings to disease, we measured lysosomal biomarkers in urine and cerebrospinal fluid (CSF) from human subjects carrying variants in LRRK2 associated with PD risk and from subjects dosed with a LRRK2 kinase inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our data demonstrate that LRRK2 can employ distinct mechanisms to control intracellular BMP levels and modulate lysosomal homeostasis depending on the tissue examined. We show that LRRK2 deletion or inhibition lowers urine BMP levels by reducing the secretion of BMP-containing vesicles from kidney into urine. In other cell types such as microglia, LRRK2-mediated inhibition of \u03b2-glucocerebrosidase (GCase), a PD-linked enzyme involved in GSL catabolism, leads to lysosomal GSL accumulation and increases BMP levels as a compensatory response to restore lysosomal homeostasis. LRRK2 inhibition normalizes lysosomal function and reduces GSL levels in preclinical models and CSF from LRRK2-PD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study highlights the therapeutic potential of LRRK2 kinase inhibition to improve PD-associated lysosomal dysfunction and supports the utility of GSLs as CSF-based biomarkers of LRRK2 activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      This work includes results from the following phase 1b study in PD patients: ClinicalTrials.gov ID: NCT03710707;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03710707?intr=dnl201&amp;rank=2\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT03710707?intr=dnl201&amp;rank=2<\/jats:ext-link>\n                      . The date of registration was 10\/18\/2018.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-025-00880-7","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T16:14:50Z","timestamp":1754496890000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["LRRK2 kinase activity regulates Parkinson\u2019s disease-relevant lipids at the lysosome"],"prefix":"10.1186","volume":"20","author":[{"given":"Michael T.","family":"Maloney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajarshi","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan V.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romeo","family":"Maciuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shababa T.","family":"Masoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maayan","family":"Agam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Caprioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Astarita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaliy V.","family":"Bondar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Lu","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonnet S.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey Cheuk-Nga","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang N.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas E.","family":"Propson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Reyzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver B.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Deen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Vocadlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"de Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Lewcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Arguello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung H.","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Huntwork-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8124-5477","authenticated-orcid":false,"given":"Anastasia G.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"880_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nature20414","volume":"539","author":"A Abeliovich","year":"2016","unstructured":"Abeliovich A, Gitler AD. Defects in trafficking Bridge Parkinson\u2019s disease pathology and genetics. Nature. 2016;539:207\u201316.","journal-title":"Nature"},{"key":"880_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00401-020-02181-3","volume":"140","author":"S Bandres-Ciga","year":"2020","unstructured":"Bandres-Ciga S, et al. Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease. Acta Neuropathol. 2020;140:341\u201358.","journal-title":"Acta Neuropathol"},{"key":"880_CR3","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/ng.3955","volume":"49","author":"D Chang","year":"2017","unstructured":"Chang D, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson\u2019s disease risk loci. Nat Genet. 2017;49:1511\u20136.","journal-title":"Nat Genet"},{"key":"880_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls MA, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18:1091\u2013102.","journal-title":"Lancet Neurol"},{"key":"880_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41531-019-0076-6","volume":"5","author":"RH Reynolds","year":"2019","unstructured":"Reynolds RH, et al. Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson\u2019s disease heritability. Npj Parkinson\u2019s Disease. 2019;5:6.","journal-title":"Npj Parkinson\u2019s Disease"},{"key":"880_CR6","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jmg.2004.024455","volume":"41","author":"O Goker-Alpan","year":"2004","unstructured":"Goker-Alpan O, et al. Parkinsonism among gaucher disease carriers. J Med Genet. 2004;41:937\u201340.","journal-title":"J Med Genet"},{"key":"880_CR7","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1093\/brain\/awx285","volume":"140","author":"LA Robak","year":"2017","unstructured":"Robak LA, et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease. Brain. 2017;140:3191\u2013203.","journal-title":"Brain"},{"key":"880_CR8","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med. 2009;361:1651\u201361.","journal-title":"N Engl J Med"},{"key":"880_CR9","doi-asserted-by":"publisher","first-page":"e0172348","DOI":"10.1371\/journal.pone.0172348","volume":"12","author":"RB Chan","year":"2017","unstructured":"Chan RB, et al. Elevated GM3 plasma concentration in idiopathic Parkinson\u2019s disease: A lipidomic analysis. PLoS ONE. 2017;12:e0172348.","journal-title":"PLoS ONE"},{"key":"880_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.nbd.2009.05.023","volume":"35","author":"Y Chu","year":"2009","unstructured":"Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in lysosomal and proteasomal markers in Parkinson\u2019s disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009;35:385\u201398.","journal-title":"Neurobiol Dis"},{"key":"880_CR11","doi-asserted-by":"publisher","first-page":"12535","DOI":"10.1523\/JNEUROSCI.1920-10.2010","volume":"30","author":"B Dehay","year":"2010","unstructured":"Dehay B, et al. Pathogenic lysosomal depletion in Parkinson\u2019s disease. J Neurosci. 2010;30:12535\u201344.","journal-title":"J Neurosci"},{"key":"880_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13024-019-0339-z","volume":"14","author":"M Huebecker","year":"2019","unstructured":"Huebecker M, et al. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson\u2019s disease. Mol Neurodegener. 2019;14:40.","journal-title":"Mol Neurodegener"},{"key":"880_CR13","doi-asserted-by":"publisher","first-page":"100661","DOI":"10.1016\/j.xcrm.2022.100661","volume":"3","author":"O Karayel","year":"2022","unstructured":"Karayel O, et al. Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson\u2019s disease. Cell Rep Med. 2022;3:100661.","journal-title":"Cell Rep Med"},{"key":"880_CR14","doi-asserted-by":"publisher","first-page":"eabj2658","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings D, et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci Transl Med. 2022;14:eabj2658.","journal-title":"Sci Transl Med"},{"key":"880_CR15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/mds.29297","volume":"38","author":"D Jennings","year":"2023","unstructured":"Jennings D, et al. LRRK2 Inhibition by BIIB122 in healthy participants and patients with Parkinson\u2019s disease. Mov Disord. 2023;38:386\u201398.","journal-title":"Mov Disord"},{"key":"880_CR16","unstructured":"K. Y. Hui et al., Functional variants in the LRRK2 gene confer shared effects on risk for Crohn\u2019s disease and Parkinson\u2019s disease. Science Translational Medicine 10, eaai7795 (2018)."},{"key":"880_CR17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1042\/BST20180462","volume":"47","author":"JH Kluss","year":"2019","unstructured":"Kluss JH, Mamais A, Cookson MR. LRRK2 links genetic and sporadic Parkinson\u2019s disease. Biochem Soc Trans. 2019;47:651\u201361.","journal-title":"Biochem Soc Trans"},{"key":"880_CR18","first-page":"561","volume":"31","author":"EK Tan","year":"2010","unstructured":"Tan EK, et al. Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat. 2010;31:561\u20138.","journal-title":"Hum Mutat"},{"key":"880_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1126\/science.aar5683","volume":"360","author":"DR Alessi","year":"2018","unstructured":"Alessi DR, Sammler E. LRRK2 kinase in Parkinson\u2019s disease. Science. 2018;360:36\u20137.","journal-title":"Science"},{"key":"880_CR20","doi-asserted-by":"publisher","first-page":"164ra161","DOI":"10.1126\/scitranslmed.3004485","volume":"4","author":"Z Sheng","year":"2012","unstructured":"Sheng Z, et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med. 2012;4:164ra161.","journal-title":"Sci Transl Med"},{"key":"880_CR21","doi-asserted-by":"publisher","first-page":"12900","DOI":"10.1038\/s41598-021-91943-4","volume":"11","author":"X Wang","year":"2021","unstructured":"Wang X, et al. Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10. Sci Rep. 2021;11:12900.","journal-title":"Sci Rep"},{"key":"880_CR22","unstructured":"Pfeffer SR. LRRK2 phosphorylation of Rab GTPases in Parkinson\u2019s disease. FEBS Letters n\/a."},{"key":"880_CR23","doi-asserted-by":"crossref","unstructured":"Steger M et al. Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 5, (2016).","DOI":"10.7554\/eLife.12813"},{"key":"880_CR24","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1016\/j.cub.2021.02.061","volume":"31","author":"CA Boecker","year":"2021","unstructured":"Boecker CA, Goldsmith J, Dou D, Cajka GG, Holzbaur ELF. Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes. Curr Biol. 2021;31:2140\u2013e21542146.","journal-title":"Curr Biol"},{"key":"880_CR25","doi-asserted-by":"publisher","first-page":"eabb2454","DOI":"10.1126\/sciadv.abb2454","volume":"6","author":"L Bonet-Ponce","year":"2020","unstructured":"Bonet-Ponce L, et al. LRRK2 mediates tubulation and vesicle sorting from lysosomes. Sci Adv. 2020;6:eabb2454.","journal-title":"Sci Adv"},{"key":"880_CR26","doi-asserted-by":"publisher","first-page":"E9115","DOI":"10.1073\/pnas.1812196115","volume":"115","author":"T Eguchi","year":"2018","unstructured":"Eguchi T, et al. LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis. Proc Natl Acad Sci. 2018;115:E9115\u201324.","journal-title":"Proc Natl Acad Sci"},{"key":"880_CR27","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1093\/hmg\/ddv314","volume":"24","author":"AG Henry","year":"2015","unstructured":"Henry AG, et al. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression. Hum Mol Genet. 2015;24:6013\u201328.","journal-title":"Hum Mol Genet"},{"key":"880_CR28","doi-asserted-by":"publisher","first-page":"e87255","DOI":"10.7554\/eLife.87255","volume":"12","author":"X Wang","year":"2023","unstructured":"Wang X, et al. Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes. eLife. 2023;12:e87255.","journal-title":"eLife"},{"key":"880_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/tra.12715","volume":"21","author":"J Gruenberg","year":"2020","unstructured":"Gruenberg J. Life in the lumen: the multivesicular endosome. Traffic. 2020;21:76\u201393.","journal-title":"Traffic"},{"key":"880_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1146\/annurev-biochem-092823-113814","volume":"93","author":"UN Medoh","year":"2024","unstructured":"Medoh UN, Abu-Remaileh M. The Bis(monoacylglycero)-phosphate hypothesis: from lysosomal function to therapeutic avenues. Annu Rev Biochem. 2024;93:447\u201369.","journal-title":"Annu Rev Biochem"},{"key":"880_CR31","doi-asserted-by":"publisher","first-page":"273ra215","DOI":"10.1126\/scitranslmed.aaa3634","volume":"7","author":"RN Fuji","year":"2015","unstructured":"Fuji RN, et al. Effect of selective LRRK2 kinase Inhibition on nonhuman primate lung. Sci Transl Med. 2015;7:273ra215.","journal-title":"Sci Transl Med"},{"key":"880_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/mds.27818","volume":"35","author":"RN Alcalay","year":"2020","unstructured":"Alcalay RN, et al. Higher urine bis(Monoacylglycerol)Phosphate levels in LRRK2 G2019S mutation carriers: implications for therapeutic development. Mov Disord. 2020;35:134\u201341.","journal-title":"Mov Disord"},{"key":"880_CR33","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s11064-010-0337-6","volume":"36","author":"HD Gallala","year":"2011","unstructured":"Gallala HD, Sandhoff K. Biological function of the cellular lipid BMP-BMP as a key activator for cholesterol sorting and membrane digestion. Neurochem Res. 2011;36:1594\u2013600.","journal-title":"Neurochem Res"},{"key":"880_CR34","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1016\/j.cell.2021.08.002","volume":"184","author":"T Logan","year":"2021","unstructured":"Logan T, et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell. 2021;184:4651\u2013e46684625.","journal-title":"Cell"},{"key":"880_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10719-021-10023-x","volume":"39","author":"K-L Wallom","year":"2022","unstructured":"Wallom K-L, et al. Glycosphingolipid metabolism and its role in ageing and Parkinson\u2019s disease. Glycoconj J. 2022;39:39\u201353.","journal-title":"Glycoconj J"},{"key":"880_CR36","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/mds.28549","volume":"36","author":"H Iwaki","year":"2021","unstructured":"Iwaki H, et al. Accelerating medicines partnership: Parkinson\u2019s disease. Genetic Resource Mov Disorders. 2021;36:1795\u2013804.","journal-title":"Genetic Resource Mov Disorders"},{"key":"880_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"A Auton","year":"2015","unstructured":"Auton A, et al. A global reference for human genetic variation. Nature. 2015;526:68\u201374.","journal-title":"Nature"},{"key":"880_CR38","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/rcm.3444","volume":"22","author":"M Strohalm","year":"2008","unstructured":"Strohalm M, Hassman M, Ko\u0161ata B, Kod\u00ed\u010dek M. mMass data miner: an open source alternative for mass spectrometric data analysis. Rapid Commun Mass Spectrom. 2008;22:905\u20138.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"880_CR39","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1021\/ac100818g","volume":"82","author":"M Strohalm","year":"2010","unstructured":"Strohalm M, Kavan D, Nov\u00e1k P, Voln\u00fd M, Havl\u00ed\u010dek V. mMass 3: A Cross-Platform software environment for precise analysis of mass spectrometric data. Anal Chem. 2010;82:4648\u201351.","journal-title":"Anal Chem"},{"key":"880_CR40","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1021\/acs.jproteome.8b00459","volume":"17","author":"X Wu","year":"2018","unstructured":"Wu X, Li L, Iliuk A, Tao WA. Highly efficient phosphoproteome capture and analysis from urinary extracellular vesicles. J Proteome Res. 2018;17:3308\u201316.","journal-title":"J Proteome Res"},{"key":"880_CR41","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41593-020-0650-6","volume":"23","author":"BJ Andreone","year":"2020","unstructured":"Andreone BJ, et al. Alzheimer\u2019s-associated PLC\u03b32 is a signaling node required for both TREM2 function and the inflammatory response in human microglia. Nat Neurosci. 2020;23:927\u201338.","journal-title":"Nat Neurosci"},{"key":"880_CR42","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench JG, et al. Optimized SgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34:184\u201391.","journal-title":"Nat Biotechnol"},{"key":"880_CR43","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41593-020-00796-z","volume":"24","author":"SR Guttikonda","year":"2021","unstructured":"Guttikonda SR, et al. Fully defined human pluripotent stem cell-derived microglia and tri-culture system model C3 production in alzheimer\u2019s disease. Nat Neurosci. 2021;24:343\u201354.","journal-title":"Nat Neurosci"},{"key":"880_CR44","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nn.4534","volume":"20","author":"H Pandya","year":"2017","unstructured":"Pandya H, et al. Differentiation of human and murine induced pluripotent stem cells to microglia-like cells. Nat Neurosci. 2017;20:753\u20139.","journal-title":"Nat Neurosci"},{"key":"880_CR45","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/nm.4189","volume":"22","author":"J Muffat","year":"2016","unstructured":"Muffat J, et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med. 2016;22:1358\u201367.","journal-title":"Nat Med"},{"key":"880_CR46","doi-asserted-by":"crossref","unstructured":"Deen MC et al. A versatile fluorescence-quenched substrate for quantitative measurement of glucocerebrosidase activity within live cells. Proceedings of the National Academy of Sciences 119, e2200553119 (2022).","DOI":"10.1073\/pnas.2200553119"},{"key":"880_CR47","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1126\/science.aan6298","volume":"358","author":"M Abu-Remaileh","year":"2017","unstructured":"Abu-Remaileh M, et al. Lysosomal metabolomics reveals V-ATPase- and mTOR-dependent regulation of amino acid efflux from lysosomes. Science. 2017;358:807\u201313.","journal-title":"Science"},{"key":"880_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13742-015-0047-8","volume":"4","author":"CC Chang","year":"2015","unstructured":"Chang CC, et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.","journal-title":"Gigascience"},{"key":"880_CR49","doi-asserted-by":"publisher","first-page":"e3428","DOI":"10.1212\/WNL.0000000000010863","volume":"95","author":"GF Crotty","year":"2020","unstructured":"Crotty GF, et al. Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers: A metabolomic study. Neurology. 2020;95:e3428\u201337.","journal-title":"Neurology"},{"key":"880_CR50","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/mds.26614","volume":"31","author":"C Marras","year":"2016","unstructured":"Marras C, et al. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson\u2019s disease. Mov Disord. 2016;31:1192\u2013202.","journal-title":"Mov Disord"},{"key":"880_CR51","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41467-017-02533-w","volume":"9","author":"AM Miranda","year":"2018","unstructured":"Miranda AM, et al. Neuronal lysosomal dysfunction releases exosomes harboring APP C-terminal fragments and unique lipid signatures. Nat Commun. 2018;9:291.","journal-title":"Nat Commun"},{"key":"880_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1194\/jlr.R084343","volume":"60","author":"T Skotland","year":"2019","unstructured":"Skotland T, Hessvik NP, Sandvig K, Llorente A. Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology. J Lipid Res. 2019;60:9\u201318.","journal-title":"J Lipid Res"},{"key":"880_CR53","doi-asserted-by":"publisher","first-page":"eaav0820","DOI":"10.1126\/scitranslmed.aav0820","volume":"12","author":"MAS Baptista","year":"2020","unstructured":"Baptista MAS, et al. LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Sci Transl Med. 2020;12:eaav0820.","journal-title":"Sci Transl Med"},{"key":"880_CR54","doi-asserted-by":"publisher","unstructured":"Merchant K, Simuni T, Fedler J. e. al, Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts. PREPRINT (Version 1) available at Research Square [https:\/\/doi.org\/10.21203\/rs.3.rs-2065993\/v1], (2022).","DOI":"10.21203\/rs.3.rs-2065993\/v1]"},{"key":"880_CR55","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1194\/jlr.E086173","volume":"59","author":"M Record","year":"2018","unstructured":"Record M, Silvente-Poirot S, Poirot M, Wakelam MJO. Extracellular vesicles: lipids as key components of their biogenesis and functions. J Lipid Res. 2018;59:1316\u201324.","journal-title":"J Lipid Res"},{"key":"880_CR56","doi-asserted-by":"publisher","first-page":"eaay1163","DOI":"10.1126\/scitranslmed.aay1163","volume":"12","author":"JC Ullman","year":"2020","unstructured":"Ullman JC, et al. Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Sci Transl Med. 2020;12:eaay1163.","journal-title":"Sci Transl Med"},{"key":"880_CR57","doi-asserted-by":"publisher","first-page":"20423","DOI":"10.1074\/jbc.R110.134452","volume":"285","author":"EB Vitner","year":"2010","unstructured":"Vitner EB, Platt FM, Futerman AH. Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem. 2010;285:20423\u20137.","journal-title":"J Biol Chem"},{"key":"880_CR58","unstructured":"(!!!. INVALID CITATION!!! (21, 27))."},{"key":"880_CR59","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00401-021-02325-z","volume":"142","author":"Y Fan","year":"2021","unstructured":"Fan Y, et al. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. Acta Neuropathol. 2021;142:475\u201394.","journal-title":"Acta Neuropathol"},{"key":"880_CR60","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.devcel.2020.11.016","volume":"56","author":"OB Davis","year":"2021","unstructured":"Davis OB, et al. NPC1-mTORC1 signaling couples cholesterol sensing to organelle homeostasis and is a targetable pathway in Niemann-Pick type C. Dev Cell. 2021;56:260\u2013e276267.","journal-title":"Dev Cell"},{"key":"880_CR61","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1093\/brain\/awv179","volume":"138","author":"RN Alcalay","year":"2015","unstructured":"Alcalay RN, et al. Glucocerebrosidase activity in Parkinson\u2019s disease with and without GBA mutations. Brain. 2015;138:2648\u201358.","journal-title":"Brain"},{"key":"880_CR62","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41531-022-00354-3","volume":"8","author":"M Kedariti","year":"2022","unstructured":"Kedariti M, et al. LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson\u2019s disease. Npj Parkinson\u2019s Disease. 2022;8:92.","journal-title":"Npj Parkinson\u2019s Disease"},{"key":"880_CR63","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1038\/s41467-019-13413-w","volume":"10","author":"D Ysselstein","year":"2019","unstructured":"Ysselstein D, et al. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson\u2019s disease patients. Nat Commun. 2019;10:5570.","journal-title":"Nat Commun"},{"key":"880_CR64","doi-asserted-by":"publisher","first-page":"eabp8869","DOI":"10.1126\/scitranslmed.abp8869","volume":"14","author":"RG Langston","year":"2022","unstructured":"Langston RG, et al. Association of a common genetic variant with Parkinson\u2019s disease is mediated by microglia. Sci Transl Med. 2022;14:eabp8869.","journal-title":"Sci Transl Med"},{"key":"880_CR65","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/hmg\/ddab294","volume":"31","author":"BM Schilder","year":"2022","unstructured":"Schilder BM, Raj T. Fine-mapping of Parkinson\u2019s disease susceptibility loci identifies putative causal variants. Hum Mol Genet. 2022;31:888\u2013900.","journal-title":"Hum Mol Genet"},{"key":"880_CR66","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1474-4422(24)00121-2","volume":"23","author":"EK Gustavsson","year":"2024","unstructured":"Gustavsson EK, et al. <em\u2009>\u2009RAB32\u2009Ser71Arg in autosomal dominant Parkinson\u2019s disease: linkage, association, and functional analyses<\/em\u2009>. Lancet Neurol. 2024;23:603\u201314.","journal-title":"Lancet Neurol"},{"key":"880_CR67","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41588-024-01787-7","volume":"56","author":"PJ Hop","year":"2024","unstructured":"Hop PJ, et al. Systematic rare variant analyses identify RAB32 as a susceptibility gene for Familial Parkinson\u2019s disease. Nat Genet. 2024;56:1371\u20136.","journal-title":"Nat Genet"},{"key":"880_CR68","unstructured":"Program TGPsG, Leonard HL. Novel Parkinson\u2019s Disease Genetic Risk Factors Within and Across European Populations. medRxiv, 2025.2003.2014.24319455 (2025)."},{"key":"880_CR69","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2105-13-120","volume":"13","author":"AK Petersen","year":"2012","unstructured":"Petersen AK, et al. On the hypothesis-free testing of metabolite ratios in genome-wide and metabolome-wide association studies. BMC Bioinformatics. 2012;13:120.","journal-title":"BMC Bioinformatics"},{"key":"880_CR70","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3389\/fnins.2020.00865","volume":"14","author":"HJ Rideout","year":"2020","unstructured":"Rideout HJ, et al. The current State-of-the Art of LRRK2-Based biomarker assay development in Parkinson\u2019s disease. Front Neurosci. 2020;14:865.","journal-title":"Front Neurosci"},{"key":"880_CR71","doi-asserted-by":"crossref","unstructured":"Di Maio R et al. LRRK2 activation in idiopathic Parkinson\u2019s disease. Sci Transl Med 10, (2018).","DOI":"10.1126\/scitranslmed.aar5429"},{"key":"880_CR72","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1111\/febs.16099","volume":"289","author":"L Bonet-Ponce","year":"2022","unstructured":"Bonet-Ponce L, Cookson MR. LRRK2 recruitment, activity, and function in organelles. FEBS J. 2022;289:6871\u201390.","journal-title":"FEBS J"},{"key":"880_CR73","doi-asserted-by":"crossref","unstructured":"Madureira M, Connor-Robson N, Wade-Martins R. LRRK2: autophagy and lysosomal activity. Front NeuroSci 14, (2020).","DOI":"10.3389\/fnins.2020.00498"},{"key":"880_CR74","doi-asserted-by":"publisher","first-page":"e87098","DOI":"10.7554\/eLife.87098","volume":"12","author":"HS Dhekne","year":"2023","unstructured":"Dhekne HS, et al. Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson\u2019s disease-linked LRRK2 kinase. eLife. 2023;12:e87098.","journal-title":"eLife"},{"key":"880_CR75","doi-asserted-by":"publisher","first-page":"e05191","DOI":"10.1016\/j.heliyon.2020.e05191","volume":"6","author":"M Karatas","year":"2020","unstructured":"Karatas M, et al. Enzyme kinetics and Inhibition parameters of human leukocyte glucosylceramidase. Heliyon. 2020;6:e05191.","journal-title":"Heliyon"},{"key":"880_CR76","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1021\/bi9002265","volume":"48","author":"RL Lieberman","year":"2009","unstructured":"Lieberman RL, D\u2019Aquino A, Ringe JD, Petsko GA. Effects of pH and Iminosugar Pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry. 2009;48:4816\u201327.","journal-title":"Biochemistry"},{"key":"880_CR77","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.chembiol.2014.06.008","volume":"21","author":"YL Tan","year":"2014","unstructured":"Tan YL, et al. ERdj3 is an Endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to gaucher\u2019s disease. Chem Biol. 2014;21:967\u201376.","journal-title":"Chem Biol"},{"key":"880_CR78","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/21541248.2016.1264352","volume":"9","author":"L Blanc","year":"2018","unstructured":"Blanc L, Vidal M. New insights into the function of Rab GTPases in the context of Exosomal secretion. Small GTPases. 2018;9:95\u2013106.","journal-title":"Small GTPases"},{"key":"880_CR79","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1083\/jcb.200911018","volume":"189","author":"C Hsu","year":"2010","unstructured":"Hsu C, et al. Regulation of exosome secretion by Rab35 and its GTPase-activating proteins TBC1D10A-C. J Cell Biol. 2010;189:223\u201332.","journal-title":"J Cell Biol"},{"key":"880_CR80","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.nbd.2011.01.029","volume":"42","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti L, et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis. 2011;42:360\u20137.","journal-title":"Neurobiol Dis"},{"key":"880_CR81","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.arr.2016.05.001","volume":"32","author":"E Eitan","year":"2016","unstructured":"Eitan E, Suire C, Zhang S, Mattson MP. Impact of lysosome status on extracellular vesicle content and release. Ageing Res Rev. 2016;32:65\u201374.","journal-title":"Ageing Res Rev"},{"key":"880_CR82","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1042\/BJ20071043","volume":"411","author":"J Peter","year":"2008","unstructured":"Peter J, Meikle, et al. Effect of lysosomal storage on bis(monoacylglycero)phosphate. Biochem J. 2008;411:71\u20138.","journal-title":"Biochem J"},{"key":"880_CR83","doi-asserted-by":"crossref","unstructured":"Showalter MR et al. The emerging and diverse roles of Bis(monoacylglycero) phosphate lipids in cellular physiology and disease. Int J Mol Sci 21, (2020).","DOI":"10.3390\/ijms21218067"},{"key":"880_CR84","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1194\/jlr.M057851","volume":"56","author":"Z Akgoc","year":"2015","unstructured":"Akgoc Z, et al. Bis(monoacylglycero)phosphate: a secondary storage lipid in the gangliosidoses. J Lipid Res. 2015;56:1006\u201313.","journal-title":"J Lipid Res"},{"key":"880_CR85","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/BF01813904","volume":"9","author":"GT Besley","year":"1986","unstructured":"Besley GT, Elleder M. Enzyme activities and phospholipid storage patterns in brain and spleen samples from Niemann-Pick disease variants: a comparison of neuropathic and non-neuropathic forms. J Inherit Metab Dis. 1986;9:59\u201371.","journal-title":"J Inherit Metab Dis"},{"key":"880_CR86","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2017.05.010","volume":"121","author":"LK Hein","year":"2017","unstructured":"Hein LK, Rozaklis T, Adams MK, Hopwood JJ, Karageorgos L. Lipid composition of microdomains is altered in neuronopathic gaucher disease sheep brain and spleen. Mol Genet Metab. 2017;121:259\u201370.","journal-title":"Mol Genet Metab"},{"key":"880_CR87","doi-asserted-by":"publisher","first-page":"104626","DOI":"10.1016\/j.nbd.2019.104626","volume":"134","author":"EM Rocha","year":"2020","unstructured":"Rocha EM, et al. LRRK2 Inhibition prevents endolysosomal deficits seen in human Parkinson\u2019s disease. Neurobiol Dis. 2020;134:104626.","journal-title":"Neurobiol Dis"},{"key":"880_CR88","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3389\/fnins.2020.00442","volume":"14","author":"A Sanyal","year":"2020","unstructured":"Sanyal A, Novis HS, Gasser E, Lin S, LaVoie MJ. LRRK2 kinase Inhibition rescues deficits in lysosome function due to heterozygous GBA1 expression in human iPSC-Derived neurons. Front Neurosci. 2020;14:442.","journal-title":"Front Neurosci"},{"key":"880_CR89","doi-asserted-by":"publisher","first-page":"15446","DOI":"10.1038\/s41598-018-33921-x","volume":"8","author":"F Atashrazm","year":"2018","unstructured":"Atashrazm F, et al. Reduced glucocerebrosidase activity in monocytes from patients with Parkinson\u2019s disease. Sci Rep. 2018;8:15446.","journal-title":"Sci Rep"},{"key":"880_CR90","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13024-015-0010-2","volume":"10","author":"D Chiasserini","year":"2015","unstructured":"Chiasserini D, et al. Selective loss of glucocerebrosidase activity in sporadic Parkinson\u2019s disease and dementia with lewy bodies. Mol Neurodegener. 2015;10:15.","journal-title":"Mol Neurodegener"},{"key":"880_CR91","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ana.24781","volume":"80","author":"G Liu","year":"2016","unstructured":"Liu G, et al. Specifically neuropathic gaucher\u2019s mutations accelerate cognitive decline in Parkinson\u2019s. Ann Neurol. 2016;80:674\u201385.","journal-title":"Ann Neurol"},{"key":"880_CR92","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/brain\/awt367","volume":"137","author":"KE Murphy","year":"2014","unstructured":"Murphy KE, et al. Reduced glucocerebrosidase is associated with increased \u03b1-synuclein in sporadic Parkinson\u2019s disease. Brain. 2014;137:834\u201348.","journal-title":"Brain"},{"key":"880_CR93","doi-asserted-by":"publisher","first-page":"e215845","DOI":"10.1001\/jamanetworkopen.2021.5845","volume":"4","author":"RA Ortega","year":"2021","unstructured":"Ortega RA, et al. Association of dual LRRK2 G2019S and GBA variations with Parkinson disease progression. JAMA Netw Open. 2021;4:e215845.","journal-title":"JAMA Netw Open"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00880-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00880-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00880-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:32:58Z","timestamp":1757345578000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00880-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["880"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00880-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.12.19.521070","asserted-by":"object"}]},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study protocols, amendments, and informed consent forms were reviewed and approved by local institutional review boards\/independent ethics committees. Written informed consent was obtained from each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following competing interests:","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"M.T.M., X.W., R.G., S.V.A., R.M., S.T.M., M.A., G.A., V.V.B, J.C., C.C., S.S.D., A.C.H., H.N.N., N.E.P., O.B.D., G.D.P., A.A.E., J.V., J.W.L., A.A., J.H.S., S.H.R., and A.G.H. were full time employees and shareholders of Denali Therapeutics during the course of this work. X.W. M.A., A.A.E. and J.D.V. are currently employees of Tenvie Therapeutics.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}